

(Translation)

Minutes of the Annual General Meeting of Shareholders for the year 2024
of
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited

Time and place

The Meeting was held on 11 April 2024 at 10.00 AM by means of electronic meeting (E-AGM) pursuant to the Emergency Decree on Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings via Electronic Means, B.E. 2563 (2020).

Attending Directors for the Meeting (The Company had 11 directors)

- | | | |
|----|-----------------------------------|--|
| 1. | M.D. Thongchai Thavichachart | Chairman of the Board of Directors and Independent Director |
| 2. | Ms. Sopawadee Lertmanaschai | Independent Director, Chairman of the Audit Committee and Member of the Nomination and Remuneration Committee |
| 3. | Pharm. Vinit Usavakidviree | Independent Director, Member of the Audit Committee |
| 4. | Asst. Prof. Lalita Hongratanawong | Independent Director, Member of the Audit Committee and Chairman of the Nomination and Remuneration Committee |
| 5. | Mr. Natthawut Viboonpatanawong | Independent Director, Chairman of the Risk Management Committee |
| 6. | Mr. Tawat Kitkungvan | Director, Member of the Nomination and Remuneration Committee |
| 7. | Mrs. Jintana Suntipisud | Director, Chairman of the Executive Committee |
| 8. | Dr. Sittichai Daengprasert | Director, Member of the Risk Management Committee, Member of the Executive Committee, President (CEO), and Executive Vice President of Research and Innovation |
| 9. | Mr. Pissanu Daengprasert | Director, Member of the Executive Committee, and Executive Vice President of Sales and Marketing |

(Translation)

- | | | |
|-----|--------------------------|---|
| 10. | Ms. Jirada Daengprasert | Director, Member of the Nomination and Remuneration Committee, Member of the Executive Committee and Executive Vice President of Finance and Accounting (CFO) |
| 11. | Mr. Sorasit Daengprasert | Director, Member of the Risk Management Committee, Member of the Executive Committee, and Executive Vice President of Manufacturing and Operations |

Attending Management for the Meeting

- | | | |
|----|-----------------------------------|--|
| 1. | Mr. Kriangkrai Rungruangthaweekul | Member of the Executive Committee and Vice President of Finance |
| 2. | Ms. Nongnuch Cheawpattayakorn | Member of the Executive Committee and Senior Quality Assurance Manager |
| 3. | Mr. Danaisuan Kunarosombat | Member of the Executive Committee and Senior Plant Manager |

Attending Auditor for the Meeting

- | | | |
|----|-------------------------------|------------------------------------|
| 1. | Ms. Kanokorn Phooripanyawanit | Auditor, KPMG Phoomchai Audit Ltd. |
| 2. | Ms. Worrawee Thanathadaphat | Auditor, KPMG Phoomchai Audit Ltd. |

Preliminaries

M.D. Thongchai Thavichachart, Chairman of the Board of Directors, who presided as the chairman of the Meeting (the “Chairman”), welcomed the shareholders to the Annual General Meeting of Shareholders of JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited for the year 2024 (the “Meeting”) and then assigned Ms. Patcharaphon Puaekbutr to act as moderator.

Ms. Patcharaphon Puaekbutr explained the details of this Meeting that it was a meeting via electronic media, a system having the standard consistent with the conditions and procedures prescribed in the Emergency Decree on Electronic Meetings, B.E. 2563 (2020), and the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). Eligible attendees at the Meeting must complete self-verification in accordance with the methods prescribed by the Company and agree to comply with the requirements for attending the Annual General Meeting of Shareholders for

(Translation)

the year 2024. This was to facilitate the shareholders and reduce their travel burden and to make the most of technology.

For the sake of transparency and to comply with the best practices for a shareholders' meeting, the Company invited Ms. Worrawee Thanathadaphat, auditor from KPMG Phoomchai Audit Ltd., to witness the vote counting.

The moderator declared to the Meeting that there were 34 shareholders of the Company attending (in person and by proxy), representing an aggregate of 316,387,200 shares, equivalent to 66.6703% of the total number of issued shares, and therefore constituting a quorum pursuant to Article 38 of the Company's Articles of Association.

Prior to follow meeting agendas, the moderator briefly explained to the shareholders the voting procedure and details of the meeting practice. The voting procedure shall be in accordance with the Company's Articles of Association, i.e., one share carries one vote. Shareholders are able to vote approval, disapproval or abstention in each agenda item. With respect to vote counting, only shareholders' votes in objection and abstention will be counted and then deducted from the total number of votes of the attending shareholders, which results in the remainder being considered approval votes for such agenda item.

Any shareholder wishing to raise a question is kindly asked to click the Chat button to pop up the tools for typing a text message in the Chat. The shareholder shall then choose the recipient and send the question to Q&A only. The shareholder is kindly asked to type a text message and press the Enter button when done to send the same, and wait for the Company's staff to contact back and confirm the question when the agenda item related to that question comes. It is requested that the shareholder shall state own name and surname and status as shareholder or proxy prior to raising any query or opinion every time.

The shareholders may cast a vote to "approve", "disapprove" or "abstain" in each agenda item. Once votes have been cast by the shareholders, the system will show a popup to ask for voting confirmation where the shareholders shall press Agree to confirm their voting. Any shareholder wishing to alter their vote may do so by clicking to vote again. The system will allow a minute of voting per agenda item. Any shareholder failing to press vote in any agenda item shall be deemed to have "approved" in such agenda item.

After casting the vote, the shareholders are asked to return to the E-Meeting window (Zoom) to continue viewing the Meeting audio and video. The staff will gather all votes from the voting system. Voting is unavailable in any agenda item for acknowledgment. Once voting is closed in any agenda item, the shareholders will no longer submit a vote or change the vote in that agenda item.

If any shareholder logs out from the system during the Meeting, the system will exclude the said shareholder's vote in that certain agenda item from the base for calculation to conform with the Notification of the Ministry of Digital Economy and Society Re: Standards for Maintaining Security of Meetings Via Electronic Means, B.E. 2563 (2020). However, the shareholder may log in to attend the Meeting at all times until the Meeting is adjourned.

(Translation)

Furthermore, as the voting procedure for this Meeting is via an online system, void ballots will not occur, except for the case of votes in a proxy form submitted to the Company in advance. Any ballot which (1) is marked in more than one box or (2) does not show true intention of the voter in regard to the voting will be deemed as a void ballot. If any shareholder or proxy delays in attending the Meeting via electronic means, the shareholder or proxy may register and attend the Meeting but will be eligible to vote only in the remaining agenda items. The Company will report to the Meeting details of the voting results for each agenda item after completion of consideration and voting in each agenda item. Nonetheless, if vote counting in certain agenda item takes more time than usual, the Company will proceed with consideration of the following agenda item to enable continuation of the Meeting, and once the staff have finished vote counting, the voting results will be immediately reported to the Shareholders' Meeting. In addition, the Company recorded this meeting by mean of video.

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to propose meeting agendas and nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2024, during 10 October 2023 to 25 November 2023. However, neither meeting agenda nor candidate was proposed and nominated by the shareholders.

The Chairman subsequently proceeded with Meeting in accordance with the following agenda.

Agenda 1 **To Acknowledge the Annual Report for the Year 2023**

The Chairman assigned Dr. Sittichai Daengprasert; President (CEO), to report the Company's performance for the year 2023.

President (CEO) informed the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider the report of the Board of Directors showing the Company's performance in the previous year.

The Board of Directors has already prepared the Directors' Report which described the Company's performance for the year 2023 as detailed in the Annual Registration Form/Annual Report for the year 2023 (56-1 One Report) which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, that Board of Directors had approved and deemed it appropriate to propose the Company's Annual Report for the year 2023 to the Shareholders' Meeting for acknowledgement.

The Company would like to informed the performance related to anti-corruption activities. The Company has prepared various charters and policies in order to provide understanding to directors, executives and employees and applied them appropriately. These included good corporate governance, duty and care to

(Translation)

stakeholders and anti-corruption. Especially, the Company had anti-corruption policy to express intention and determine guidelines for anti-corruption, also build up good culture in business's operations. The Company expects that such policy will create assurance to stakeholders and regulators. The Company prohibited directors, executives, and employees to participate or involve with all activities that might cast to corruption, both direct and indirect ways. For instance, bribery, give or receive unusual entertainment and/or gift. In addition, the Company set aside measures over whistleblowing channels, investigations, punishments, protection of whistleblowers and protection to persons who refuse corruption.

In 2023, the Company provided training to directors, executives, and employees in relation to anti-corruption by mean of self-learning through e-learning and all personnels have signed for acknowledgement over the measures. There were 100.00% of directors, executives and employees learned and signed the measures. Furthermore, the Company had no claim arose from corruption.

The Company is studying information about Thai Private Sector Collective Action Against Corruption and preparing assessment form under Thai Private Sector Collective Action Against Corruption for certifying as member of the collective action.

Presently, the Company operates in several businesses, which comprised

1. Manufacturing of conventional medicine, dietary supplement and herbal product for humans
2. Manufacturing of dietary supplement for pets
3. Manufacturing and distributing hemodialysis solution and medical supplies for dialysis
4. Product research and development, scientific testing in laboratory and training to entrepreneurs.

Significant developments in the year 2023 and business plan for 2024

President (CEO) informed the Meeting that the Company had significant development in dietary supplement; namely "Suphap Osot™ Black Sesame and Rice Bran Oil", by having good market awareness. The Company then became leader in TV Home Shopping market, which generated 60% of total revenues from Own Brand under this marketing channel. In addition, the acquisition a research and development company i.e. CDIP (Thailand) PCL. and new product development e.g. ID Lab brought the Company into a leader in innovation.

The Company's manufacturing had also taken pace of development from expanding production facilities at Lamphun plant to support various demand from customers. Moreover, the expansion of AB dialysis solution, operated by Grace Water Med Company Limited (a subsidiary of the Company) resulted to double capacity. The Company also took care of business operations under ESG by installing solar roof top for electricity generating for factory use purposes.

President (CEO) then gave the shareholders an opportunity to raise questions about the Company's performance for the year 2023.

(Translation)

No shareholder had any question about the Company's performance for the year 2023.

The Meeting acknowledged the Annual Report for the year 2023.

Agenda 2 **To Consider Approving the Financial Statements for the Year Ended 31 December 2023**

The Chairman assigned Ms. Jirada Daengprasert; Executive Vice President of Finance and Accounting (CFO), to report the Company's financial statements for the year ended 31 December 2023.

Executive Vice President of Finance and Accounting (CFO) explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider approving the statement of financial position and statement of comprehensive income at the end of the previous fiscal year, and Article 57 of the Company's Articles of Association and Section 112 of the Public Limited Companies Act, B.E. 2535 (1992), prescribe that the Board of Directors must cause the balance sheet (statement of financial position) and the profit and loss account (statement of comprehensive income) at the end of the Company's fiscal year to be made and propose to the Shareholders' Meeting for consideration and approval in the Annual General Meeting of Shareholders. The Board of Directors must have such the balance sheet and profit and loss account audited by an auditor before presenting them to the Shareholders' Meeting.

The Board of Directors caused the financial statements for the year ended 31 December 2023 and had been audited by the Company's auditor and reviewed by the Audit Committee. The financial statements were presented in the Annual Registration Form/Annual Report for the year 2023 (56-1 One Report) which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). In addition, that Board of Directors had approved and deemed it appropriate to propose the financial statements for the year ended 31 December 2023; which have been audited by the auditor and reviewed by the Audit Committee, to the Shareholders' Meeting for approval.

Significant financial information for the year 2023

1. Operating results: Total revenues from sales and services for the year 2023 was reported at Baht 575.59 million, which had 25.7% increased in all the Company's product types. The Company emphasis in core revenues, which comprised OEM and Own Brand products. Furthermore, hemodialysis solution products generated revenue by 11.2% of total revenues. The Company had 25.1% gross profit margin for the year 2023 and 4.4% net profit margin higher than the year 2022.

(Translation)

2. Financial position: Non-current assets increased because of the expansion of production facilities and Lamphun province and business combinations. As a result, total liabilities increased.
3. Cash flows: In 2023, the Company had improvement in cash flows from operating activities. Whilst, significant negative cash flows from investing activities were from acquiring fixed assets for business expansion purposes.

Executive Vice President of Finance and Accounting (CFO) gave the shareholders an opportunity to raise questions about the financial statements for the year ended 31 December 2023.

Since no shareholder had any question, the Chairman asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the financial statements for the year ended 31 December 2023 with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

(Translation)

Agenda 3 To Consider Approving the Appropriation of Net Profit to be Legal Reserve for the Performance for the Year Ended 31 December 2023 and Omission of the Annual Dividend Payment for the Year 2023

The Chairman assigned Ms. Jirada Daengprasert, Executive Vice President of Finance and Accounting (CFO), to report the appropriation of net profit to be legal reserve for the performance for the year ended 31 December 2023 and omission of the annual dividend payment for the year 2023.

Executive Vice President of Finance and Accounting (CFO) explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider appropriating profits and fund as reserve fund, and Article 52 of the Company's Articles of Association and Section 116 of the Public Limited Companies Act, B.E. 2535 (1992), prescribe that the Company must appropriate part of its annual net profit as a reserve fund in the amount not less than 5% of the annual net profit less accumulated loss brought forward (if any) until this reserve fund reaches the amount not less than 10% of the registered capital.

In addition, Article 49 of the Company's Articles of Association prescribes that dividend payment may not be announced unless it is pursuant to the resolution of the Shareholders' Meeting, and Section 115 of the Public Limited Companies Act, B.E. 2535 (1992), prescribes that dividend payment must be approved by the shareholders' meeting.

The Company has policy to pay dividend at the rate not less than 40% of the net profit according to the Company's separate financial statements after deduction of all reserve funds as stipulated by law and Company's Articles of Association. However, such dividend payment must not exceed the retained profit according to the Company's separate financial statements. In addition, in the case that the Company's financial statements have accumulated deficit, the Company will not consider making dividend payment. The Company may consider paying dividend at the rate lower than the abovementioned rate depending on the Company's performance, financial position and liquidity, as well as the necessity to utilise the working capital for its business operation, the Company's future business expansion plan and other factors relating to the Company's management as deemed appropriate by the Board of Directors.

According to the performance for the year ended 31 December 2023, the Company had net profit and deficit reported in separate financial statements amounting to Baht 8,589,287.88 and Baht (2,303,862.41), respectively. The Board of Directors therefore rendered an approval resolution and deemed it appropriate to propose that the the Shareholders' Meeting consider approving the omission of appropriation of net profit as legal reserve and to omit the annual dividend payment for the year 2023 since the Company had outstanding deficit in the separate financial statements.

(Translation)

Executive Vice President of Finance and Accounting (CFO) gave the shareholders an opportunity to raise questions about the omission of appropriation of net profit as legal reserve and omission of the annual dividend payment for the year 2023.

Since no shareholder had any question, the Chairman asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the omission of appropriation of net profit to be the legal reserve, and to omit the annual dividend payment for the year 2023, with the unanimous vote of the shareholders who attended the Meeting and casted their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

Agenda 4 To Consider Approving the Appointment of Directors in Place of Directors who are to be Retired by Rotation

The Chairman explained to the Meeting that, at the Annual General Meeting of Shareholders for the year 2024, there are 4 directors who are to retire by rotation as follows:

- (1) Ms. Sopawadee Lertmanaschai Independent Director
- (2) Mr. Vinit Usavakidviree Independent Director
- (3) Mrs. JIntana Santipisud Director
- (4) Mr. Sorasit Daengprasert Director

(Translation)

The Chairman asked directors to retire by rotation to leave from the meeting room. Such directors will attend the Meeting after this agenda has completed. Then, the Chairman asked Asst. Prof Lalita Hongratanawong, the Chairman of the Nomination and Remuneration Committee, to explain to the Meeting agenda.

The Chairman of the Nomination and Remuneration Committee explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider electing the directors in place of directors retiring by rotation, and Article 18 prescribes that, at every Annual General Meeting of Shareholders, at least one-thirds of the directors shall retire from office. If their number is not a multiple of three, then the number nearest to one-thirds shall retire from office. The directors who have been in office longest shall retire. A retiring director is eligible for re-election.

In this appointment of directors in place of directors retiring by rotation, the Nomination and Remuneration Committee considered it and concluded that the nominated directors were considered in compliance with the Company's nomination procedures, had qualifications in accordance with the related rules and appropriate for the Company's business operation. Furthermore, the individuals to be nominated as independent directors had qualifications in accordance with the law on the requirements of independent directors. Profiles of the abovementioned directors are shown in the Detailed Profiles of the Candidates to be Elected as Directors in Place of Directors Retiring by Rotation delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 2).

The Board of Directors, exclusive of directors having interest, was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting consider approving the re-appointment of the retiring directors for another term.

In accordance with the principles of good corporate governance with respect to the treatment of shareholders' rights, the Company gave the shareholders an opportunity to nominate candidates to be considered and elected as directors in advance for the Annual General Meeting of Shareholders for the year 2024, during 10 October 2023 to 25 November 2023. However, no candidate was nominated by the shareholders.

The Chairman of the Nomination and Remuneration Committee gave the shareholders an opportunity to raise questions about the appointment of directors to replace those retiring by rotation.

Since no shareholder had any question, the Chairman asked the Meeting to consider and vote on this agenda item. The candidates with the highest number of votes in respective order shall be elected as directors in a number equal to the number of directors eligible or elected at that time. In the event that there are equal votes amongst the candidates elected in order of respective high numbers of votes while the number of such candidates exceeds the number of directors to be available or elected at that time, the Chairman shall have a casting vote.

(Translation)

The moderator clarified to the Meeting the voting method for this agenda item. The election will be conducted on individual basis. After that, the moderator reported the resolution as follow.

Resolution: Approved the appointment of the directors who were to be retired by rotation as follows.

- (1) Approved the appointment of Ms. Sopawadee Lertmanaschai to resume the Independent Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

- (2) Approved the appointment of Mr. Vinit Usavakidviree to resume the Independent Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

(Translation)

- (3) Approved the appointment of Mrs. Jintana Santipisud to resume the Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	284,398,300	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	284,398,300	100.00000

- (4) Approved the appointment of Mr. Sorasit Daengprasert to resume the Director position for another term of office with the votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	284,633,300	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	284,633,300	100.00000

The said appointed directors returned to the meeting room.

Agenda 5 To Consider Approving the Determination of Remuneration of Directors and Subcommittees for the Year 2024

The Chairman asked Asst. Prof Lalita Hongratanawong, the Chairman of the Nomination and Remuneration Committee, to explain the determination of remuneration of directors and subcommittees for the year 2024.

The Chairman of the Nomination and Remuneration Committee explained to the Meeting that under Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider determining the remuneration of directors, and Article 34 prescribes that the bonus and remuneration of directors shall be fixed by the Shareholders' Meeting. Accordingly, it was deemed appropriate

(Translation)

to propose that the Shareholders' Meeting consider approving the determination of remuneration of directors and subcommittees for the year 2024, as detailed below.

Types of Directors	Meeting Allowances (Unit: Baht)	
	Per Time	Per Quarter
Chairman of the Board of Directors	40,000	15,000
Director and Independent Director	12,000	-
Chairman of the Audit Committee	30,000	10,000
Member of the Audit Committee	15,000	-
Chairman of the Risk Management Committee	10,000	-
Member of the Risk Management Committee	7,500	-
Chairman of the Nomination and Remuneration Committee	10,000	-
Member of the Nomination and Remuneration Committee	7,500	-

Notes:

- (1) The directors' remuneration above does not apply to directors who are the Company's executives that receive monthly remuneration.
- (2) The Company is entitled to additionally pay the directors' remuneration based on the Company's annual turnover. The total directors' remuneration shall not exceed 0.25% of the gross income per the Company's annual consolidated financial statements.

The Board of Directors was in favor of the proposal by the Nomination and Remuneration Committee, and therefore, rendered an approval resolution and deemed it appropriate to propose that the Shareholders' Meeting for consideration and approval of the determination of remuneration of directors and subcommittees for the year 2024 as proposed.

The Chairman of the Nomination and Remuneration Committee gave the shareholders an opportunity to raise questions about the determination of remuneration of directors and subcommittees for the year 2024.

Since no shareholder had any question, the Chairman asked the Meeting to consider and vote on this agenda item where the approval resolution shall be passed by votes of no less than two-thirds of the total number of votes of the shareholders attending the Meeting.

The moderator explained the voting method and then reported the resolution as follow.

(Translation)

Resolution: Approved the determination of remuneration of directors and subcommittees for the year 2024 as proposed, with the unanimous vote of all votes of the shareholders who attended the Meeting, as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

Agenda 6 To Consider Approving the Appointment of Company's Auditors and Specification of Auditors' Remuneration for the Year 2024

The Chairman asked Ms. Sopawadee Lertmanaschai, the Chairman of the Audit Committee, to explain the appointment of Company's auditors and specification of auditors' remuneration for the year 2024.

The Chairman of the Audit Committee explained to the Meeting that Article 44 of the Company's Articles of Association prescribes that the Annual General Meeting of Shareholders must consider and appoint an auditor and determine the auditor's remuneration; Article 60 prescribes that the Annual General Meeting of Shareholders must appoint an auditor every year and may re-elect any such retired auditor to resume their position, and Article 61 prescribes that the Annual General Meeting of Shareholders must determine the auditor's remuneration. Therefore, it was deemed appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and specification of auditor's remuneration for the year 2024.

The Audit Committee had considered the appointment of auditor and specification of auditor's remuneration for the year 2024 by taking into account the auditor's experience and performance quality in the previous year and, as a result, the Audit Committee selected KPMG Phoomchai Audit Ltd. as the Company's auditor with details below.

- (1) Miss Kanokon Phooriphanyawanit Certified Public Accountant No. 10512, or
- (2) Miss Nadsasin Wattanapaisal Certified Public Accountant No. 10767, or
- (3) Miss Sukanya Rodkroh Certified Public Accountant No. 12089,

(Translation)

In case of the said auditors were unable to perform the works, KPMG Phoomchai Audit Ltd. will provide other auditors from the same company who have the qualifications and do not have prohibited characteristics as prescribed by law, to audit and certify the Company's financial statements. The Audit Committee specified the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31 December 2024 in the amount not exceeding Baht 2,300,000 (excluding out of pocket expenses and VAT (if any)). Detailed of auditor's remuneration was illustrated in the Annual Registration Form/Annual Report for the year 2023 (56-1 One Report) Topic "Auditor and its affiliates' remuneration" which has been delivered in QR code format to the shareholders for downloading in digital format, together with the invitation letter of this Meeting (Enclosure 1). Profiles and experiences of the abovementioned auditors are shown in the Detailed Profiles and Experiences of Auditors for the Year 2024 as delivered to the shareholders, together with the Invitation Letter of this Meeting (Enclosure 3).

All of the Company's subsidiaries use the same audit office to audit and certify the financial statements. The Board of Directors will ensure that the subsidiaries will prepare financial statements in a timely manner. In addition, the said auditors and audit office do not have any relationship and/or interest with the Company, its subsidiaries, major shareholders or related persons thereof.

The Board of Directors was in favor of the Audit Committee's proposal, and therefore, resolved to approve and deemed it appropriate to propose that the Shareholders' Meeting consider approving the appointment of auditor and the specification of auditor's remuneration for the year 2024 as proposed.

The Chairman of the Audit Committee gave the shareholders an opportunity to raise questions about the appointment of Company's auditors and specification of auditors' remuneration for the year 2024.

Since no shareholder had any question, the Chairman asked the Meeting to consider and vote on this agenda item where the approval resolution required a majority vote of the shareholders attending the Meeting and casting their votes.

The moderator explained the voting method and then reported the resolution as follow.

Resolution: Approved the appointment of (1) Miss Kanokon Phooriphanyawanit, Certified Public Accountant No. 10512, or (2) Miss Nadsasin Wattanapaisal, Certified Public Accountant No. 10767, or (3) Miss Sukanya Rodkroh Certified Public Accountant No. 12089, from KPMG Phoomchai Audit Ltd., or other auditors from the same company, which have qualifications and do not have characteristics as restricted by the laws, to audit and certify the Company's financial statements, and specify the auditor's remuneration for auditing and certifying the Company's consolidated and separate financial statements for the year ended 31

(Translation)

December 2024 in the amount not exceeding Baht 2,300,000 (excluding out of pocket expenses and VAT (if any)), with the unanimous vote of the shareholders who attended the Meeting and cast their votes as follows.

	Number of Votes	Calculated as percentage of the total number of votes of the shareholders who attended the Meeting and cast their votes
Approved	316,398,500	100.0000
Disapproved	0	0.0000
Abstained	0	Not included as base for voting calculation
Void Ballot(s)	0	0.0000
Total votes of the Meeting	316,398,500	100.00000

Agenda 7 Other Business (if any)

The Chairman gave the shareholders an opportunity to raise questions or propose agenda items other than those shown in the agenda.

The moderator informed the Meeting that Ms. Usa Sumatelak; a proxy from Thai Investors Association: TIA, gave a suggestion that Thai Investors Association has a policy to encourage listed companies in the Stock Exchange of Thailand conducting Annual/Extraordinary Meeting of Shareholders in both of on-site and online i.e. hybrid meeting. This will enable shareholders to facilitate meeting, communicating and discussing among shareholders, executives and directors. This practice is announced by the Securities Exchange and Commission's Circular Letter No. SEC Nor.Ror. (Wor) 2/2567 (2023) Re. Asking of Cooperation about Conducting Annual General Meeting of Shareholders dated 10 January 2024. TIA then suggested the Company to conduct hybrid meeting as proposed.

The Chairman thankful for the suggestion and will consider to conduct meeting as proposed by TIA in the next time.

No shareholder raised any question or proposed any other agenda item. The Chairman therefore thanked the shareholders and declared the Meeting closed.

(Translation)

The Meeting adjourned at 11.30 AM.

(M.D. Thongchai Thavichachart)

Chairman of the Meeting

(Ms. Jirada Daengprasert)

Company Secretary